Clinical Trials Logo

Pharmacological Action clinical trials

View clinical trials related to Pharmacological Action.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06040853 Not yet recruiting - Clinical trials for Pharmacological Action

Postoperative Pain in Laparoscopic Radical Prostatectomy Surgery With Tranexamic Acid: Analgesia? Hiperalgesia?

Start date: September 30, 2023
Phase: Phase 4
Study type: Interventional

Prostate cancer is the most diagnosed cancer among men today. Radical prostatectomy is a surgery that significantly reduces disease-related mortality. The laparoscopic technique, on the other hand, is preferred because it shortens the hospital stay, faster recovery and less postoperative pain.In this study, it was planned to investigate the analgesic or hyperalgesic effects of tranexamic acid, which is widely used in the management of bleeding in trauma, orthopedic, genitourinary and gynecological surgeries. Routine noninvasive monitoring (ECG, Spo2, NIBP) will be performed when participatient are taken to the operating table without premedication. After midazolam is administered, intubation will be performed by administering 1mg/kg lidocaine, 3mg/kg propofol, 2mcg/kg fentanyl, 0.6mg/kg rocuronium. Anesthesia will be maintained with desflurane with a MAC of 1. A 0.1-0.5 mcg/kg/min remifentanil infusion will be administered by targeting 40-60 values with BIS monitoring. After intubation, 15mg/kg tranexamic acid will be given 10 minutes before the incision, and 100 mg/h infusion will be administered until the skin is closed. The control group will be given 100 ml of saline.1mg/kg tramadol and 1gr parol will be administered 30 minutes before the end of the operation. The primary objectives of the study were to learn the VAS (Visual analog scale) score at 0.6,12, 24,48,72 hours, time to first analgesic requirement, and analgesic requirement within 24 hours. Secondary purposes are to determine the amount of antiemetic used, at the beginning of the operation, Hg at the first hour and postoperative 6 hours, complications and side effects (such as DVT, pulmonary embolism).

NCT ID: NCT05553496 Not yet recruiting - Clinical trials for Pharmacological Action

Assessment of Rituximab Therapeutic Response Versus Conventional Treatment

Start date: September 25, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Prospective interventional comparative study to compare the efficacy of Rituximab versus Conventional treatment in Refractory Nephrotic Syndrome including patients on triple immunosuppression protocols.

NCT ID: NCT05453045 Not yet recruiting - Clinical trials for Pharmacological Action

Pharmacokinetics and Excretion of Albendazole and Its Metabolites in Saliva

Start date: July 18, 2022
Phase: N/A
Study type: Interventional

This project will develop and assess the feasibility and acceptability of a salive-based assay to monitor adherence to Mass Drug Administration (MDA) campaigns within Soil-transmitted helminthiasis (STH) control programs, evaluating the salive and serum pharmacokinetics of ALBENDAZOLE (ABZ) and its metabolites.The final goal is to obtain a field ready tool for the measurement of adherence to anthelmintic treatment at a community level that serves as a coverage/adherence indicator and a reference standard for other monitoring tools.

NCT ID: NCT04320277 Not yet recruiting - Clinical trials for Pharmacological Action

Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.

BARI-COVID
Start date: May 16, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

There is no specific antiviral treatment recommended for COVID-19, and no vaccine is currently available. Baricitinib, an anti-Janus kinase inhibitor (anti-JAK) acting against JAK1 and JAK2. The drug was found capable to reduce or interrupt the passage of the virus into target cells, and to inhibit the JAK1- and JAK2-mediated cytokine release. The drug was licensed for the treatment of rheumatoid arthritis at the daily dose of 4 mg/orally, with excellent results in terms of clinical response and a good safety profile. Since baricitinib does not interact with antivirals due to its prevalent renal elimination, it may be used in combination.The evidence on the advantageous action of baricitinib on viral entry and cytokine outbreak constituted the rationale to perform a trial on patients with mild to moderate COVID-19 infection receiving baricitinib combined with antiviral therapy.

NCT ID: NCT03953287 Not yet recruiting - Clinical trials for Pharmacological Action

Pharmacokinetic Study of Paracetamol.

Para1523
Start date: August 18, 2019
Phase: Phase 1
Study type: Interventional

Brief Summary: The study evaluate the absorption rate and pharmacodynamic of different formulation of paracetamol either in the form of normal tablets or a new rapid absorbable gelation capsule formulation "Paracetamol1523" by determining T-max and area under the response curve of paracetamol in blood concentration as well as from clinical effects after intake. Data is entered on data sheet in anonymous form and processed. The results are presented in anonymous form by publication and lecture. Experts are given the supplement: "The applicant's rights in a biomedical research project

NCT ID: NCT03904303 Not yet recruiting - Clinical trials for Pharmacological Action

Test of a New Gel-based Colon Cleansing Agent Compared to Moviprep

Start date: June 1, 2019
Phase: Phase 1
Study type: Interventional

Crossover study comparing Moviprep (for bowel cleansing) with a new gel-based colon cleansing agent before colonoscopy